1. Home
  2. MYNZ

MYNZ

Mainz Biomed N.V.

Logo Mainz Biomed N.V.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-15-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Mainz Biomed NV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. Its main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Founded: 2021 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 22.0M IPO Year: 2021
Target Price: $3.00 AVG Volume (30 days): 86.1K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.62 EPS Growth: N/A
52 Week Low/High: $0.85 - $6.07 Next Earning Date: 04-09-2024
Revenue: $895,479 Revenue Growth: 69.00%
Revenue Growth (this year): 194.59% Revenue Growth (next year): 191.28%

Share on Social Networks: